Q-omics provides the consensus-scored RNF182 profile across patient tissues and cancer cell-line models. RNF182 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, RNF182 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, RNF182 RNA expression shows 16,539 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight STAD, KIRC, and TGCT as cancer lineages where RNF182 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF182 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF182 survival associations across molecular data types. RNF182 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF182 RNA expression–survival associations across cancer types. High RNF182 expression shows unfavorable associations in STAD, LUSC, UCEC, UVM and BLCA, but favorable associations in MESO. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify STAD as the clearest survival context for RNF182 RNA expression.
This table summarizes RNF182 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RNF182. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF182 shows lower tumor expression in KIRC, KICH, LUAD, LUSC and THCA and higher tumor expression in BLCA. The KIRC box plot shows higher RNF182 RNA expression in normal versus tumor tissue (log2 FC = −1.514, t-test p < 0.001).
This table shows molecular features associated with RNF182 in patient tissues and cancer cell lines. In patient samples, RNF182 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF182 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BONE.
